Unicycive Therapeutics Inc

NASDAQ:UNCY   12:56:02 PM EDT
2.90
-0.15 (-4.92%)
Other Pre-Announcement

Unicycive Therapeutics Announces Q3 Loss Per Share Of $0.37

Published: 11/11/2021 14:24 GMT
Unicycive Therapeutics Inc (UNCY) - Unicycive Therapeutics Announces Third Quarter 2021 Financial Results.
Q3 Loss per Share $0.37.
As of September 30, 2021, Cash and Cash Equivalents Totaled $18 Million.
Expect to Receive Confirmatory Guidance on Renazorb Regulatory Pathway From FDA in Q4 2021.
Planned Completion of Pre-clinical Studies With Uni-494 in First Half of 2022.